Latest News about JNJ
Recent news which mentions JNJ
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
October 28, 2024
From Benzinga
Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease
October 28, 2024
From Benzinga
3 Dividend Growth Stocks You Can Buy and Hold Forever
October 26, 2024
From Motley Fool
Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas
October 25, 2024
From Benzinga
Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry
October 24, 2024
From Benzinga
Meet the Only 2 Game-Changing Businesses With a Higher Credit Rating Than the U.S. Government
October 24, 2024
From Motley Fool
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime
October 23, 2024
From Motley Fool
From Motley Fool
Justice Department's Trustee Program Alleges Johnson & Johnson's Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid Liability
October 22, 2024
From Benzinga
What's Going On With Kenvue Stock Monday?
October 21, 2024
From Benzinga
Tylenol, Listerine Maker Kenvue Under Activist Spotlight With Starboard Value Stake — Overhaul Ahead For The Johnson & Johnson Spinoff?
October 20, 2024
From Benzinga
All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year
October 19, 2024
From Motley Fool
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
October 19, 2024
From Motley Fool
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
October 18, 2024
From Benzinga
3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now
October 18, 2024
From Motley Fool
This Magnificent Dividend Stock Is as Healthy as It Gets
October 17, 2024
Tickers
JNJ
From Motley Fool
Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say
October 16, 2024
From Benzinga
From Motley Fool
Cancer Drugs Propel J&J Beyond Wall Street Estimates
October 15, 2024
From Benzinga
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
October 15, 2024
Tickers
JNJ
From Motley Fool
From Benzinga
Chipmaker Stocks Sink On ASML Earnings Leak, Oil Eyes Worst 1-Day Drop This Year, Small Caps Rally: What's Driving Markets Tuesday?
October 15, 2024
From Benzinga
From Benzinga
Johnson & Johnson's Q3 Earnings: Revenue And EPS Beat On Strong Cancer Drug Sales, Revises Annual Outlook To Reflect V-Wave Acquisition
October 15, 2024
From Benzinga
Wall Street On Edge As Nasdaq Nears Record High, Oil Prices Plummet: Strategist Says There's Opportunity If Resilience Continues
October 15, 2024
From Benzinga
Jim Cramer Says Earnings Season Will Fuel Market's Record Run, But Warns Of This 'Horrendous' Headwind That Could Apply Brakes To Rally
October 15, 2024
From Benzinga
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
October 14, 2024
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.